A new European consortium of industry and academic partners created in September 2013, focused on the development of ophthalmic drugs
“Drug Discovery and Development of Novel Eye Therapeutics”
Age-related macular degeneration, diabetic retinopathy, and corneal inflammation are significant causes of irreversible blindness with increasing prevalence as the EU population ages and the “diabetes epidemic” expands. There is an unmet clinical need for more effective treatments to halt or reverse these diseases.
3D-NET establishes a network of industry and academic partners, who exchange knowledge and people, and whose combined S&T expertise will enhance the discovery and development of drugs that target ocular pathologies (retinal vessel permeability, unwanted blood vessel growth, inflammation and cell degeneration).
Follow Us on Facebook, Twitter and LinkedIn
Marie Curie Industry-Academia Partnerships and Pathways (IAPP)
Project Number (612218/3D-NET)